MENA BIOLOGICS & BIOSIMILARS MARKET ANALYSIS

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ MENA BIOLOGICS & BIOSIMILARS MARKET ANALYSIS

2. MENA BIOLOGICS & BIOSIMILARS MARKET ANALYSIS MENA Biologics & Biosimilars Market, by Product Type (Influenza Vaccines, Factor VIII, (Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate and Novoeight), Erythropoietin (Epoetin Alfa (Binocrit(2000IU and 4000IU) (Eprex (2000IU and 4000IU) Darbepoietin Alfa (Aranesp) and Epoetin Alfa-epbx (Retacrit, Recormon)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP)), by Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), and by Region/Country (Gulf and Egypt) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

3. Figure 1: MENA Biologics & Biosimilars MarketShare (%) Analysis, ByTherapeutic Application, 2020

4. The MENA biologics & biosimilars market is estimated to be valued at US$ 442.5 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027). • MENA Biologics & Biosimilars Market - Impact of Coronavirus (Covid-19) Pandemic • The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. • The lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to declining outpatients’ visits, manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases such as cardiovascular, diabetic and cancer. • Moreover, the coronavirus pandemic has negatively impacted development, production, and supply of drugs and affected businesses of various companies operating in the healthcare sector across the globe. The pandemic has led to closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of products. • Thus, COVID-19 pandemic has affected the economy in three main ways: 1) by directly affecting the production and demand,  2) by creating disruptions in distribution channels, and 3) through its financial impact on companies and financial markets. • Supply chain and manufacturing activities in India, China, the U.S., and other countries have been disrupted due to lockdowns, while countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation of drugs and medical devices. • Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the MENA biologics & biosimilars market during the forecast period.

6. Rising strategic collaborations with leading pharmaceutical companies and research institutes for the development of novel biosimilar is driving growth of the MENA biologics & biosimilars market • Key players are involved in strategic collaborations with leading pharmaceutical companies and research institutes for the development of novel biosimilar. Such strategic collaborations are expected to create conducive environment for growth of the MENA biologics and biosimilar market in the near future. • For instance, in July 2018, Xbrane Biopharma AB (Xbrane) and STADA Arzneimittel AG (STADA) entered into a collaborative agreement for the development of Lucentis (ranibizumab) biosimilar to treat eye diseases, mainly neovascular age-related macular degeneration, diabetic-related macular edema, and retinal vein occlusion, covering Europe, the U.S., and some MENA and APAC markets. • In November 2017, Octapharma AG, in collaboration with Project SHARE, donated 30.5 million units of human cell-line derived recombinant factor VIII product, Nuwiq, for the treatment of patients with hemophilia A in emerging economies such as Bangladesh, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Myanmar, Nepal, and others.

7. MENA Biologics & Biosimilars Market- Restraints • High cost of treatment for hemophilia is a major factor, which is expected to hinder the market growth during the forecast period. Hemophilia is associated with high aggregate costs and imposes a high financial burden on individuals and healthcare systems in emerging economies. Hemophilia is a chronic condition that requires lifelong treatment, with individual costs varying based on disease severity, complications, and treatment regimen. • For instance, according to a cohort study conducted by National Center for Biotechnology Information (NCBI) in 2015, hemophilia treatment is expensive, particularly for patients with severe hemophilia. According to the study, severe hemophilia is associated with greater annual costs in both types of hemophilia. For instance, according to the study in NCBI in 2015, the annual cost required for the treatment of hemophilia A is around US$ 84,766.9 and hemophilia B is around US$ 122,877. Patients with factor VIII inhibitors have costs 3.3 times higher than patients without factor VIII inhibitors. Thus, high cost of therapy is expected to hinder the market growth during the forecast period.

8. Figure 2: MENA Biologics & Biosimilars Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

9. MENA Biologics & Biosimilars Market- Competitive Landscape • Key players operating in the MENA biologics & biosimilars market include F. Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs • CMI Press Releases

11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

12. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

13. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/